Pth (parathyroid hormone) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: Pth (parathyroid hormone) Rattus norvegicus
Analyze
Symbol: Pth
Name: parathyroid hormone
RGD ID: 3440
Description: Enables hormone activity; peptide hormone receptor binding activity; and type 1 parathyroid hormone receptor binding activity. Involved in several processes, including Rho protein signal transduction; negative regulation of chondrocyte differentiation; and regulation of bone mineralization. Acts upstream of or within adenylate cyclase-activating G protein-coupled receptor signaling pathway and intracellular calcium ion homeostasis. Located in extracellular space. Used to study several diseases, including chronic kidney disease; hyperphosphatemia; nephrocalcinosis; osteoporosis; and secondary hyperparathyroidism. Biomarker of autosomal dominant hypocalcemia; kidney failure (multiple); osteoporosis; and secondary hyperparathyroidism. Human ortholog(s) of this gene implicated in several diseases, including chronic kidney disease; diabetes mellitus (multiple); familial isolated hypoparathyroidism; hyperphosphatemia; and secondary hyperparathyroidism. Orthologous to human PTH (parathyroid hormone); PARTICIPATES IN parathyroid hormone signaling pathway; INTERACTS WITH 1,25-Dihydroxy-16-ene-vitamin D3; 24,25-Dihydroxyvitamin D; 3',5'-cyclic AMP.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: hypothalamic parathyroid hormone; parathyrin; PTH-(1-84); Pth1; Pthr1
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Black Rat
Alliance Orthologs
More Info more info ...
Latest Assembly: GRCr8 - GRCr8 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81176,942,901 - 176,946,034 (-)NCBIGRCr8GRCr8GRCr8
GRCr8 Ensembl1176,943,102 - 176,946,034 (-)EnsemblGRCr8
mRatBN7.21167,508,121 - 167,511,530 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1167,508,598 - 167,511,530 (-)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx1175,843,980 - 175,846,912 (-)NCBIUTH_Rnor_SHR_UtxUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01183,030,070 - 183,033,002 (-)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0UTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01175,725,437 - 175,728,369 (-)NCBIUTH_Rnor_WKY_Bbb_1.0UTH_Rnor_WKY_Bbb_1.0
Rnor_6.01178,215,829 - 178,218,761 (-)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1178,215,829 - 178,218,761 (-)Ensemblrn6Rnor6.0
Rnor_5.01185,183,456 - 185,186,388 (-)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.41171,240,596 - 171,243,528 (-)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera1165,378,267 - 165,381,199 (-)NCBICelera
RGSC_v3.11171,360,529 - 171,363,462 (-)NCBI
Cytogenetic Map1q33NCBI
JBrowse:




Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(-)-epigallocatechin 3-gallate  (ISO)
1,25-Dihydroxy-16-ene-vitamin D3  (EXP)
17beta-estradiol  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (ISO)
24,25-Dihydroxyvitamin D  (EXP,ISO)
3',5'-cyclic AMP  (EXP)
3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (EXP)
3,3',4,4',5-pentachlorobiphenyl  (EXP)
3-\{1-[3-(dimethylamino)propyl]-1H-indol-3-yl\}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione  (ISO)
8-Br-cAMP  (ISO)
adenine  (EXP)
alfacalcidol  (EXP)
aluminium atom  (ISO)
aluminium(0)  (ISO)
ammonium chloride  (EXP)
arsane  (ISO)
arsenic atom  (ISO)
benzo[a]pyrene  (ISO)
bis(2-ethylhexyl) phthalate  (EXP)
bisphenol A  (EXP)
cadmium dichloride  (EXP)
calcidiol  (EXP)
calciol  (EXP,ISO)
calcitriol  (EXP,ISO)
calcium atom  (EXP,ISO)
calcium carbonate  (ISO)
calcium(0)  (EXP,ISO)
canagliflozin  (EXP)
captopril  (ISO)
CGP 52608  (ISO)
cinacalcet  (ISO)
copper atom  (EXP)
copper(0)  (EXP)
corticosterone  (EXP)
dexamethasone  (ISO)
epoxiconazole  (ISO)
ethanol  (EXP)
flavonoids  (EXP)
furosemide  (EXP)
gallium nitrate  (EXP)
hydrogen chloride  (ISO)
ketoconazole  (EXP)
lead diacetate  (EXP)
lithium atom  (EXP,ISO)
lithium carbonate  (ISO)
lithium hydride  (EXP,ISO)
Maxacalcitol  (EXP,ISO)
menaquinone  (EXP)
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide  (ISO)
nickel atom  (ISO)
paricalcitol  (ISO)
phenytoin  (ISO)
phosphorus atom  (EXP)
phosphorus(.)  (EXP)
protein kinase inhibitor  (EXP)
quercetin  (ISO)
raloxifene  (ISO)
resveratrol  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (ISO)
sodium fluoride  (EXP,ISO)
tamoxifen  (EXP)
tannic acid  (ISO)
Terfenadine  (ISO)
theophylline  (EXP)
Trapidil  (EXP)
trichostatin A  (ISO)
uranium atom  (EXP)
vanadyl sulfate  (ISO)
vinclozolin  (EXP)
vitamin D  (ISO)
vitamin K  (ISO)
warfarin  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
adenylate cyclase-activating G protein-coupled receptor signaling pathway  (IDA,IMP,ISO)
bone mineralization  (IEA,ISO)
bone resorption  (TAS)
calcium ion homeostasis  (IEA,ISO)
cell-cell signaling  (IBA,IDA)
homeostasis of number of cells within a tissue  (ISO)
intracellular calcium ion homeostasis  (IDA,IEA,ISO)
magnesium ion homeostasis  (IEA,ISO)
negative regulation of apoptotic process in bone marrow cell  (ISO)
negative regulation of bone mineralization involved in bone maturation  (IMP)
negative regulation of chondrocyte differentiation  (IMP)
negative regulation of gene expression  (IEA,ISO)
ossification  (TAS)
phosphate ion homeostasis  (IEA,ISO)
positive regulation of bone mineralization  (IDA,IEA,ISO)
positive regulation of cell proliferation in bone marrow  (ISO)
positive regulation of D-glucose import across plasma membrane  (IEA,ISO,ISS)
positive regulation of gene expression  (IMP)
positive regulation of glycogen biosynthetic process  (IEA,ISO,ISS)
positive regulation of inositol phosphate biosynthetic process  (IEA,ISO)
positive regulation of ossification  (IDA)
positive regulation of osteoclast proliferation  (ISO)
positive regulation of signal transduction  (ISO)
positive regulation of transcription by RNA polymerase II  (ISO)
regulation of gene expression  (ISO)
response to cadmium ion  (IEP)
response to ethanol  (IEP)
response to fibroblast growth factor  (IEP)
response to lead ion  (IEP)
response to nutrient levels  (IEP)
response to parathyroid hormone  (IEP)
response to vitamin D  (IEP)
response to xenobiotic stimulus  (IEP)
Rho protein signal transduction  (IMP)

Cellular Component
extracellular region  (IEA)
extracellular space  (IBA,IDA,IEA,ISO)

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. Arnold A, etal., J Clin Invest. 1990 Oct;86(4):1084-7.
2. Serum vitamin D levels in children with recurrent otitis media. Cayir A, etal., Eur Arch Otorhinolaryngol. 2013 Mar 30.
3. Impact of frequent nocturnal hemodialysis on myocardial mechanics and cardiomyocyte gene expression. Chan CT, etal., Circ Cardiovasc Imaging. 2012 Jul;5(4):474-80. doi: 10.1161/CIRCIMAGING.111.971606. Epub 2012 May 30.
4. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. Chertow GM, etal., N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3.
5. Restoration of bone mineralization by cinacalcet is associated with a significant reduction in calcitriol-induced vascular calcification in uremic rats. De Schutter TM, etal., Calcif Tissue Int. 2012 Nov;91(5):307-15. doi: 10.1007/s00223-012-9635-0. Epub 2012 Aug 28.
6. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. De Schutter TM, etal., Kidney Int. 2013 Mar 13. doi: 10.1038/ki.2013.34.
7. New potent calcimimetics: II. Discovery of benzothiazole trisubstituted ureas. Deprez P, etal., Bioorg Med Chem Lett. 2013 Apr 15;23(8):2455-9. doi: 10.1016/j.bmcl.2013.01.077. Epub 2013 Feb 8.
8. Loss-of-function mutations of CYP24A1, the vitamin D 24- hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. Dinour D, etal., J Urol. 2013 Mar 4. pii: S0022-5347(13)03464-2. doi: 10.1016/j.juro.2013.02.3188.
9. Vitamin D Treatment and Mortality in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Duranton F, etal., Am J Nephrol. 2013 Mar 5;37(3):239-248.
10. The effect of PTH(1-34) on fracture healing during different loading conditions. Ellegaard M, etal., J Bone Miner Res. 2013 Apr 13. doi: 10.1002/jbmr.1957.
11. Dietary phosphate binding and loading alter kidney angiotensin-converting enzyme mRNA and protein content in 5/6 nephrectomized rats. Eraranta A, etal., Am J Nephrol. 2012;35(5):401-8. doi: 10.1159/000337942. Epub 2012 Apr 19.
12. Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Fisher A, etal., Clin Interv Aging. 2013;8:239-56. doi: 10.2147/CIA.S38856. Epub 2013 Feb 25.
13. Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats. Fisher JE, etal., Bone. 2012 Jun;50(6):1332-42. doi: 10.1016/j.bone.2012.03.004. Epub 2012 Mar 14.
14. New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic AMP. Fujita T, etal., J Biol Chem 2002 Jun 21;277(25):22191-200.
15. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
16. Age-related changes in gap junctional intercellular communication in osteoblastic cells. Genetos DC, etal., J Orthop Res. 2012 Dec;30(12):1979-84. doi: 10.1002/jor.22172. Epub 2012 Jun 13.
17. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
18. Parathyroid hormone gene polymorphism and secondary hyperparathyroidism in hemodialysis patients. Gohda T, etal., Am J Kidney Dis. 2002 Jun;39(6):1255-60.
19. Mutual up-regulation of thyroid hormone and parathyroid hormone receptors in rat osteoblastic osteosarcoma 17/2.8 cells. Gu WX, etal., Endocrinology 2001 Jan;142(1):157-64.
20. Significance of HCG to distinguish parathyroid carcinoma from benign disease and in adding prognostic information: a hospital based study from Nepal. Gupta SP, etal., Asian Pac J Cancer Prev. 2013;14(1):325-7.
21. Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. Haller M, etal., PLoS One. 2012;7(7):e39229. doi: 10.1371/journal.pone.0039229. Epub 2012 Jul 30.
22. A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet. Haq N, etal., Int Urol Nephrol. 2013 Mar 26.
23. Role of phytoestrogenic oils in alleviating osteoporosis associated with ovariectomy in rats. Hassan HA, etal., Cytotechnology. 2012 Nov 18.
24. Epigenetic Methylation of Parathyroid CaR and VDR Promoters in Experimental Secondary Hyperparathyroidism. Hofman-Bang J, etal., Int J Nephrol. 2012;2012:123576. doi: 10.1155/2012/123576. Epub 2012 Oct 10.
25. Ferric Citrate Hydrate, a New Phosphate Binder, Prevents the Complications of Secondary Hyperparathyroidism and Vascular Calcification. Iida A, etal., Am J Nephrol. 2013 Mar 23;37(4):346-358.
26. Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor result in selective loss of PTH-stimulated phospholipase C activity. Iida-Klein A, etal., J Biol Chem. 1997 Mar 14;272(11):6882-9.
27. Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats. Jung S, etal., J Hypertens. 2012 Nov;30(11):2182-91. doi: 10.1097/HJH.0b013e328357c049.
28. Parathyroid hormone (1-34) regulates integrin expression in vivo in rat osteoblasts. Kaiser E, etal., J Cell Biochem 2001;83(4):617-30.
29. Parathyroid hormone (PTH) suppresses rat PTH/PTH-related protein receptor gene promoter. Kawane T, etal., Biochem Biophys Res Commun 2001 Sep 21;287(2):313-22.
30. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. Kestenbaum B, etal., J Am Coll Cardiol. 2011 Sep 27;58(14):1433-41. doi: 10.1016/j.jacc.2011.03.069.
31. Excessive ethanol consumption under exposure to lead intensifies disorders in bone metabolism: A study in a rat model. Kupraszewicz E and Brzoska MM, Chem Biol Interact. 2013 Jan 30;203(2):486-501. doi: 10.1016/j.cbi.2013.01.002.
32. The parathyroid hormone (PTH)/PTH-related peptide receptor mediates actions of both ligands in murine bone. Lanske B, etal., Endocrinology. 1998 Dec;139(12):5194-204.
33. Parathyroid hormone signaling in bone and kidney. Lee M and Partridge NC, Curr Opin Nephrol Hypertens. 2009 Jul;18(4):298-302. doi: 10.1097/MNH.0b013e32832c2264.
34. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Lee YK, etal., Clin Nephrol. 2013 Feb;79(2):136-42. doi: 10.5414/CN107362.
35. A comparison of the anabolic effects of rat and bovine parathyroid hormone (1-34) in ovariectomized rats. Li M, etal., J Musculoskelet Neuronal Interact. 2001 Sep;2(1):77-83.
36. Impaired bone formation with a high-protein diet in rats with adriamycin-induced nephrotic syndrome. Lim AY, etal., Kidney Blood Press Res. 2012;35(6):438-44. doi: 10.1159/000336361. Epub 2012 Jun 6.
37. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. London GM, etal., J Am Soc Nephrol. 2008 Sep;19(9):1827-35. doi: 10.1681/ASN.2007050622. Epub 2008 May 14.
38. The parathyroid hormone receptorsome and the potential for therapeutic intervention. Mahon MJ Curr Drug Targets. 2012 Jan;13(1):116-28.
39. CHRONIC AUTOIMMUNE ATROPHIC GASTRITIS ASSOCIATED WITH PRIMARY HYPERPARATHYROIDISM: A TRANSVERSAL PROSPECTIVE STUDY. Massironi S, etal., Eur J Endocrinol. 2013 Feb 27.
40. Retention of fetuin-A in renal tubular lumen protects the kidney from nephrocalcinosis in rats. Matsui I, etal., Am J Physiol Renal Physiol. 2013 Mar;304(6):F751-60. doi: 10.1152/ajprenal.00329.2012. Epub 2013 Jan 23.
41. Parathyroid hormone regulates the expression of the receptor protein tyrosine phosphatase, OST-PTP, in rat osteoblast-like cells. Mauro LJ, etal., Endocrinology. 1996 Mar;137(3):925-33. doi: 10.1210/endo.137.3.8603605.
42. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
43. The Bone-Protective Effect of Genistein in the Animal Model of Bilateral Ovariectomy: Roles of Phytoestrogens and PTH/PTHR1 Against Post-Menopausal Osteoporosis. Miao Q, etal., Int J Mol Sci. 2012;13(1):56-70. doi: 10.3390/ijms13010056. Epub 2011 Dec 22.
44. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. Moe SM, etal., J Bone Miner Res. 2011 Nov;26(11):2672-81. doi: 10.1002/jbmr.485.
45. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
46. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
47. Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study. Panuccio V, etal., BMC Nephrol. 2012 Oct 9;13:134. doi: 10.1186/1471-2369-13-134.
48. A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism. Parkinson DB and Thakker RV, Nat Genet. 1992 May;1(2):149-52.
49. Rho and Rho kinase are involved in parathyroid hormone-stimulated protein kinase C alpha translocation and IL-6 promoter activity in osteoblastic cells. Radeff JM, etal., J Bone Miner Res. 2004 Nov;19(11):1882-91. Epub 2004 Aug 16.
50. GOA pipeline RGD automated data pipeline
51. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
52. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
53. Comprehensive gene review and curation RGD comprehensive gene curation
54. Calcium deficiency reduces circulating levels of FGF23. Rodriguez-Ortiz ME, etal., J Am Soc Nephrol. 2012 Jul;23(7):1190-7. doi: 10.1681/ASN.2011101006. Epub 2012 May 10.
55. Occurrence of cardiovascular calcifications in normal, aging rats. Roosens B, etal., Exp Gerontol. 2012 Aug;47(8):614-9. doi: 10.1016/j.exger.2012.05.012. Epub 2012 May 24.
56. Vitamin D receptor interactions with the rat parathyroid hormone gene: synergistic effects between two negative vitamin D response elements. Russell J, etal., J Bone Miner Res 1999 Nov;14(11):1828-37.
57. The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program. Saab G, etal., J Clin Endocrinol Metab. 2012 Dec;97(12):4414-21. doi: 10.1210/jc.2012-2001. Epub 2012 Oct 12.
58. Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice. Santana AC, etal., Nephrol Dial Transplant. 2013 Jan 22.
59. Mineral metabolites and CKD progression in African Americans. Scialla JJ, etal., J Am Soc Nephrol. 2013 Jan;24(1):125-35. doi: 10.1681/ASN.2012070713. Epub 2012 Dec 14.
60. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Segawa H, etal., Am J Physiol Renal Physiol. 2009 Sep;297(3):F671-8. doi: 10.1152/ajprenal.00156.2009. Epub 2009 Jul 1.
61. Parathyroid hormone (PTH)-(1-14) and -(1-11) analogs conformationally constrained by alpha-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor. Shimizu N, etal., J Biol Chem. 2001 Dec 28;276(52):49003-12. Epub 2001 Oct 16.
62. Phosphorus as an early marker of morbidity and mortality in type 2 chronic kidney disease diabetic patients. Silva AP, etal., J Diabetes Complications. 2013 Mar 22. pii: S1056-8727(13)00053-6. doi: 10.1016/j.jdiacomp.2013.02.007.
63. Effects of dietary Pi on the renal Na+-dependent Pi transporter NaPi-2 in thyroparathyroidectomized rats. Takahashi F, etal., Biochem J. 1998 Jul 1;333 ( Pt 1):175-81.
64. Fibroblast growth factor 23 enhances renal klotho abundance. Takenaka T, etal., Pflugers Arch. 2013 Mar 7.
65. Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). van Ballegooijen AJ, etal., Am J Cardiol. 2013 Feb 1;111(3):418-24. doi: 10.1016/j.amjcard.2012.10.021. Epub 2012 Nov 17.
66. Polymorphisms in the vitamin d receptor gene and parathyroid hormone gene in the development and progression of diabetes mellitus and its chronic complications, diabetic nephropathy and non-diabetic renal disease. Vedralova M, etal., Kidney Blood Press Res. 2012;36(1):1-9. doi: 10.1159/000339021. Epub 2012 Jun 18.
67. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)). Watanabe A, etal., J Toxicol Sci. 2012;37(3):617-29.
68. Studies on the DIDS-binding site of monocarboxylate transporter 1 suggest a homology model of the open conformation and a plausible translocation cycle. Wilson MC, etal., J Biol Chem. 2009 Jul 24;284(30):20011-21. doi: 10.1074/jbc.M109.014217. Epub 2009 May 27.
69. Two Novel Vitamin D Receptor Modulators with Similar Structures Exhibit Different Hypercalcemic Effects in 5/6 Nephrectomized Uremic Rats. Wu-Wong JR, etal., Am J Nephrol. 2013 Mar 20;37(4):310-319.
70. Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats. Wu-Wong JR, etal., Life Sci. 2013 Feb 7;92(2):161-6. doi: 10.1016/j.lfs.2012.11.018. Epub 2012 Dec 19.
71. Cadmium impact and osteoporosis: mechanism of action. Youness ER, etal., Toxicol Mech Methods. 2012 Sep;22(7):560-7. doi: 10.3109/15376516.2012.702796.
72. Effects of phosphonoformic acid and renagel on renal type IIa sodium-dependent phosphate cotransporter mRNA expression in hyperphosphatemia rats. Zeng M, etal., Ren Fail. 2012;34(3):358-63. doi: 10.3109/0886022X.2011.647341. Epub 2012 Jan 20.
73. Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD. Zhang Q, etal., J Am Soc Nephrol. 2011 Apr;22(4):664-72. Epub 2011 Feb 18.
Additional References at PubMed
PMID:90087   PMID:3628009   PMID:6321505   PMID:7588314   PMID:11606467   PMID:12488435   PMID:12581861   PMID:12631114   PMID:14514685   PMID:14517210   PMID:14672346   PMID:15514034  
PMID:15601867   PMID:15601870   PMID:15910753   PMID:16494524   PMID:17565271   PMID:17696759   PMID:17992255   PMID:18165223   PMID:18583400   PMID:19075196   PMID:19129257   PMID:19423655  
PMID:19628670   PMID:19674967   PMID:19723499   PMID:19968565   PMID:20097749   PMID:20627105   PMID:20971569   PMID:21048959   PMID:21076856   PMID:21209610   PMID:21343254   PMID:23344572  
PMID:24103811   PMID:24259513   PMID:24904057   PMID:24940803   PMID:26669699   PMID:27989797   PMID:29529595   PMID:29633272   PMID:33945189  


Genomics

Comparative Map Data
Pth
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81176,942,901 - 176,946,034 (-)NCBIGRCr8GRCr8GRCr8
GRCr8 Ensembl1176,943,102 - 176,946,034 (-)EnsemblGRCr8
mRatBN7.21167,508,121 - 167,511,530 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1167,508,598 - 167,511,530 (-)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx1175,843,980 - 175,846,912 (-)NCBIUTH_Rnor_SHR_UtxUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01183,030,070 - 183,033,002 (-)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0UTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01175,725,437 - 175,728,369 (-)NCBIUTH_Rnor_WKY_Bbb_1.0UTH_Rnor_WKY_Bbb_1.0
Rnor_6.01178,215,829 - 178,218,761 (-)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1178,215,829 - 178,218,761 (-)Ensemblrn6Rnor6.0
Rnor_5.01185,183,456 - 185,186,388 (-)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.41171,240,596 - 171,243,528 (-)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera1165,378,267 - 165,381,199 (-)NCBICelera
RGSC_v3.11171,360,529 - 171,363,462 (-)NCBI
Cytogenetic Map1q33NCBI
PTH
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh381113,492,054 - 13,496,181 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1113,492,054 - 13,496,181 (-)Ensemblhg38GRCh38
GRCh371113,513,601 - 13,517,728 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 361113,470,177 - 13,474,143 (-)NCBIBuild 36Build 36hg18NCBI36
Build 341113,470,177 - 13,474,143NCBI
Celera1113,639,772 - 13,643,738 (-)NCBICelera
Cytogenetic Map11p15.3NCBI
HuRef1113,193,715 - 13,197,681 (-)NCBIHuRef
CHM1_11113,512,571 - 13,516,537 (-)NCBICHM1_1
T2T-CHM13v2.01113,584,795 - 13,588,918 (-)NCBIT2T-CHM13v2.0
Pth
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm397112,984,783 - 112,987,879 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl7112,984,787 - 112,987,777 (-)EnsemblGRCm39 EnsemblGRCm39
GRCm387113,385,576 - 113,388,672 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl7113,385,580 - 113,388,570 (-)Ensemblmm10GRCm38
MGSCv377120,529,090 - 120,532,087 (-)NCBIMGSCv37MGSCv37mm9NCBIm37
MGSCv367113,176,759 - 113,179,753 (-)NCBIMGSCv36mm8
Celera7113,358,705 - 113,361,703 (-)NCBICelera
Cytogenetic Map7F1NCBI
cM Map759.19NCBI
Pth
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495541428,825,651 - 28,831,117 (-)Ensembl
ChiLan1.0NW_00495541428,828,389 - 28,831,417 (-)NCBIChiLan1.0ChiLan1.0
PTH
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v2915,932,137 - 15,936,264 (-)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan11115,894,484 - 15,898,611 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01113,653,777 - 13,657,901 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11113,347,829 - 13,351,951 (-)NCBIPanPan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1113,347,838 - 13,351,802 (-)EnsemblpanPan2panpan1.1
PTH
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.12136,417,062 - 36,419,967 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl2136,417,058 - 36,419,967 (-)EnsemblcanFam3CanFam3.1
Dog10K_Boxer_Tasha2135,920,892 - 35,923,798 (-)NCBIDog10K_Boxer_TashaDog10K_Boxer_Tasha
ROS_Cfam_1.02137,300,338 - 37,303,244 (-)NCBIROS_Cfam_1.0ROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl2137,300,334 - 37,303,244 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.12136,558,731 - 36,561,637 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.02136,734,945 - 36,737,853 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.02137,024,013 - 37,026,919 (-)NCBIUU_Cfam_GSD_1.0UU_Cfam_GSD_1.0
Pth
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_02440494749,049,606 - 49,050,285 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365285,083,596 - 5,084,030 (+)EnsemblSpeTri2.0 Ensembl
SpeTri2.0NW_0049365285,081,569 - 5,084,030 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
PTH
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl245,757,398 - 45,760,415 (+)EnsemblsusScr11Sscrofa11.1
Sscrofa11.1245,757,398 - 45,760,433 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2249,290,017 - 49,290,981 (-)NCBISscrofa10.2Sscrofa10.2susScr3
PTH
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1151,327,555 - 51,330,810 (+)NCBIChlSab1.1ChlSab1.1chlSab2
Vero_WHO_p1.0NW_023666038148,907,988 - 148,910,728 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Pth
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046247665,489,800 - 5,492,871 (-)EnsemblHetGla_female_1.0 EnsemblhetGla2HetGla_female_1.0 Ensembl
HetGla 1.0NW_0046247665,489,857 - 5,492,777 (-)NCBIHetGla 1.0HetGla 1.0hetGla2
Pth
(Rattus rattus - black rat)
Black Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Rrattus_CSIRO_v1288,133,074 - 88,136,091 (+)NCBIRrattus_CSIRO_v1

Variants

.
Variants in Pth
16 total Variants
miRNA Target Status (No longer updated)

Predicted Target Of
Summary Value
Count of predictions:35
Count of miRNA genes:27
Interacting mature miRNAs:33
Transcripts:ENSRNOT00000019199
Prediction methods:Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (GRCr8)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1578778Pur4Proteinuria QTL 43.30.003urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)1160111531262090437Rat
1354646Kidm18Kidney mass QTL 185.7kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1160573753266453731Rat
1578780Cm52Cardiac mass QTL 523.30.0001heart mass (VT:0007028)heart wet weight (CMO:0000069)1137611478182611478Rat
2302378Insul11Insulin level QTL 113.25blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1153679879198679879Rat
1578770Stresp23Stress response QTL 23kidney sympathetic nerve activity (VT:0004050)stimulated renal sympathetic nerve activity to basal renal sympathetic nerve activity ratio (CMO:0001786)1132760429191848948Rat
70160Bw18Body weight QTL 185.7body mass (VT:0001259)body weight (CMO:0000012)1153679879205813246Rat
8694166Bw147Body weight QTL 1476.830.001body mass (VT:0001259)body weight gain (CMO:0000420)1153788989198788989Rat
1600397Edcs4Endometrial carcinoma susceptibility QTL 42.2uterus morphology trait (VT:0001120)percentage of study population developing endometrioid carcinoma during a period of time (CMO:0001759)1176288899270518180Rat
631199Cm23Cardiac mass QTL 234.60.0004heart left ventricle mass (VT:0007031)heart left ventricle wet weight (CMO:0000071)1142582336182383862Rat
1354636Lmblg1Limb length QTL 16.4tibia length (VT:0004357)tibia length (CMO:0000450)1160573753210707719Rat
1549837Hcar15Hepatocarcinoma resistance QTL 150.05liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1162548015270518180Rat
152025235Bw194Body weight QTL 1944.86body mass (VT:0001259)1132966869252856240Rat
61341Bp26Blood pressure QTL 26arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1139442053223964440Rat
1598853Memor3Memory QTL 34.5exploratory behavior trait (VT:0010471)total horizontal distance resulting from voluntary locomotion in an experimental apparatus (CMO:0001443)1152919152268496042Rat
1354634Kidm12Kidney mass QTL 123.9kidney mass (VT:0002707)right kidney wet weight (CMO:0000082)1160573753210707719Rat
4889428Stresp24Stress response QTL 240.05heart pumping trait (VT:2000009)absolute change in electrocardiographic low frequency R-R spectral component to high frequency R-R spectral component ratio (CMO:0002162)1165278545210278545Rat
152025232Bw192Body weight QTL 1923.93body mass (VT:0001259)1127329268206393015Rat
1578759Uae30Urinary albumin excretion QTL 303.30.003urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1160111531262090437Rat
61343Bp28Blood pressure QTL 28arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1161077990206077990Rat
724521Uae1Urinary albumin excretion QTL 13.80.0001urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)199645382182701046Rat
1358902Bw47Body weight QTL 471.67body mass (VT:0001259)body weight (CMO:0000012)199645382221502378Rat
61347Bp197Blood pressure QTL 1974.2arterial blood pressure trait (VT:2000000)blood pressure measurement (CMO:0000003)1168063662213063662Rat
61348Bp30Blood pressure QTL 302.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1159894717207261263Rat
8655649Arrd1Age-related retinal degeneration QTL 14.89retinal layer morphology trait (VT:0003727)percentage of study population developing retinopathy during a period of time (CMO:0002453)1109493780193400781Rat
2303622Vencon6Ventilatory control QTL 60.001respiration trait (VT:0001943)respiration rate (CMO:0000289)1163992710208992710Rat
7771612Cm80Cardiac mass QTL 808.4heart left ventricle mass (VT:0007031)heart left ventricle weight (CMO:0000776)1146080545243492863Rat
731168Bp154Blood pressure QTL 1543.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1103779152223964440Rat
631205Bp196Blood pressure QTL 19640.0001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)198879955208479939Rat
1300158Bp173Blood pressure QTL 1733.48arterial blood pressure trait (VT:2000000)blood pressure time series experimental set point of the baroreceptor response (CMO:0002593)1155359438194575574Rat
631206Niddm40Non-insulin dependent diabetes mellitus QTL 40blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1140833106185833106Rat
737828Hcas3Hepatocarcinoma susceptibility QTL 34.9liver integrity trait (VT:0010547)liver tumorous lesion volume to total liver volume ratio (CMO:0001082)1153679879232414077Rat
1354661Bw33Body weight QTL 335.2body mass (VT:0001259)body weight (CMO:0000012)1160573753266453731Rat
1358886Bp260Blood pressure QTL 2603.67arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1160574007235238518Rat
1331751Bp199Blood pressure QTL 1993.60022arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)1116099376191260518Rat
724531Uae5Urinary albumin excretion QTL 54urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)1160111426262090599Rat
1641895Bp298Blood pressure QTL 298arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1132760429191848948Rat
1354580Scort1Serum corticosterone level QTL 13.4blood corticosterone amount (VT:0005345)blood corticosterone level (CMO:0001172)1154961463266453731Rat
70209Niddm23Non-insulin dependent diabetes mellitus QTL 232.82blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1162753891207753891Rat
634315Niddm45Non-insulin dependent diabetes mellitus QTL 457.16blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1153680016182383862Rat
634314Niddm44Non-insulin dependent diabetes mellitus QTL 44blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)151941022208479811Rat
61379Bp44Blood pressure QTL 4419.2arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1153680016183564652Rat
1331793Bp200Blood pressure QTL 2003.71601arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1102780511182384005Rat
2312420Pur17Proteinuria QTL 177.10.0001urine protein amount (VT:0005160)urine total protein excretion rate (CMO:0000756)1172718770228180370Rat
6893347Bw98Body weight QTL 980.20.53body mass (VT:0001259)body weight (CMO:0000012)1143092939188092939Rat
1354591Cm36Cardiac mass QTL 364.1heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1111949780210707719Rat
2312558Glom17Glomerulus QTL 173.90.001kidney glomerulus morphology trait (VT:0005325)index of glomerular damage (CMO:0001135)1175967553200707874Rat
10059597Bp377Blood pressure QTL 3773.420.025arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)134565911208798288Rat
631519Pia11Pristane induced arthritis QTL 115.3joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)193903998191260518Rat
6893361Bw104Body weight QTL 1040.590.27body mass (VT:0001259)body weight (CMO:0000012)1143092939188092939Rat
724562Rends1Renal damage susceptibility QTL 10.05kidney glomerulus integrity trait (VT:0010546)index of glomerular damage (CMO:0001135)1139442053223964440Rat
738006Anxrr14Anxiety related response QTL 1440.00035locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)1140048073185048073Rat
1558645Bw55Body weight QTL 553.20.004body mass (VT:0001259)body weight (CMO:0000012)1143092939188092939Rat
1354615Cm32Cardiac mass QTL 325.2heart left ventricle mass (VT:0007031)heart left ventricle wet weight (CMO:0000071)1111949780210707719Rat
1582204Livw1Liver weight QTL 13.60.0003liver mass (VT:0003402)liver weight to body weight ratio (CMO:0000633)1170078537182384005Rat
634348Bp138Blood pressure QTL 138arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1135021436178317588Rat
1354610Bw34Body weight QTL 344.1body mass (VT:0001259)body weight (CMO:0000012)1160573753266453731Rat
738028Anxrr12Anxiety related response QTL 124.90.00001locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)1140048073185048073Rat
1354620Kidm19Kidney mass QTL 194kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1160573753210707719Rat
8693608Alc24Alcohol consumption QTL 242.30.74drinking behavior trait (VT:0001422)calculated ethanol drink intake rate (CMO:0001615)1159863716177663210Rat
1576310Schws2Schwannoma susceptibility QTL 20.029nervous system integrity trait (VT:0010566)percentage of study population developing trigeminal nerve neurilemmomas during a period of time (CMO:0002017)1153788989198788989Rat
1354618Kidm15Kidney mass QTL 155kidney mass (VT:0002707)left kidney wet weight (CMO:0000083)1165707719210707719Rat
6903303Scl34Serum cholesterol QTL 342.50.0033blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)1173363824227535316Rat
631654Bp107Blood pressure QTL 107arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1135021436180021436Rat
631544Bp84Blood pressure QTL 845.6arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1132760429191190115Rat
152025212Bw190Body weight QTL 1905.7body mass (VT:0001259)1132966869206393015Rat
631548Bp88Blood pressure QTL 8850.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1140915717185915717Rat
1358189Cstrr1Cold stress response QTL 10.0001catecholamine amount (VT:0010543)urine norepinephrine level (CMO:0001629)1132760429191848948Rat
1354606Bp246Blood pressure QTL 2463.6arterial blood pressure trait (VT:2000000)pulse pressure (CMO:0000292)1111949780228180370Rat
7411599Foco11Food consumption QTL 1118.50.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)1153788989198788989Rat
1354602Bw35Body weight QTL 3512.2body mass (VT:0001259)body weight (CMO:0000012)1160573753210707719Rat

Markers in Region
D1Wox35  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr81176,946,831 - 176,946,985 (+)Marker Load Pipeline
mRatBN7.21167,512,327 - 167,512,481 (+)MAPPERmRatBN7.2
Rnor_6.01178,219,559 - 178,219,712NCBIRnor6.0
Rnor_5.01185,187,186 - 185,187,339UniSTSRnor5.0
RGSC_v3.41171,244,326 - 171,244,479UniSTSRGSC3.4
RGSC_v3.41171,244,325 - 171,244,479RGDRGSC3.4
Celera1165,381,997 - 165,382,150UniSTS
RGSC_v3.11171,364,259 - 171,364,413RGD
RH 3.4 Map11317.39RGD
RH 3.4 Map11317.39UniSTS
RH 2.0 Map1872.4RGD
Cytogenetic Map1q34UniSTS
D1Mco32  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21167,512,331 - 167,512,469 (+)MAPPERmRatBN7.2
Rnor_6.01178,219,563 - 178,219,700NCBIRnor6.0
Rnor_5.01185,187,190 - 185,187,327UniSTSRnor5.0
RGSC_v3.41171,244,329 - 171,244,467RGDRGSC3.4
RGSC_v3.41171,244,330 - 171,244,467UniSTSRGSC3.4
Celera1165,382,001 - 165,382,138UniSTS
RGSC_v3.11171,364,263 - 171,364,401RGD
Cytogenetic Map1q34UniSTS
D1Arb30  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21167,512,365 - 167,512,576 (+)MAPPERmRatBN7.2
Rnor_6.01178,219,597 - 178,219,807NCBIRnor6.0
Rnor_5.01185,187,224 - 185,187,434UniSTSRnor5.0
RGSC_v3.41171,244,363 - 171,244,574RGDRGSC3.4
RGSC_v3.41171,244,364 - 171,244,574UniSTSRGSC3.4
Celera1165,382,035 - 165,382,245UniSTS
RGSC_v3.11171,364,297 - 171,364,508RGD
Cytogenetic Map1q34UniSTS
Pth  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21167,508,848 - 167,509,264 (+)MAPPERmRatBN7.2
Rnor_6.01178,216,080 - 178,216,495NCBIRnor6.0
Rnor_5.01185,183,707 - 185,184,122UniSTSRnor5.0
RGSC_v3.41171,240,847 - 171,241,262UniSTSRGSC3.4
Celera1165,378,518 - 165,378,933UniSTS
Cytogenetic Map1q34UniSTS


Expression

RNA-SEQ Expression

alimentary part of gastrointestinal system
circulatory system
ectoderm
endocrine system
endoderm
exocrine system
hemolymphoid system
hepatobiliary system
integumental system
mesenchyme
mesoderm
musculoskeletal system
nervous system
renal system
reproductive system
respiratory system
14 2 19 17 21 1 11 1 6 38 20 6 8 3 7 20

Sequence


Ensembl Acc Id: ENSRNOT00000019199   ⟹   ENSRNOP00000019199
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8 Ensembl1176,943,102 - 176,946,034 (-)Ensembl
mRatBN7.2 Ensembl1167,508,598 - 167,511,530 (-)Ensembl
Rnor_6.0 Ensembl1178,215,829 - 178,218,761 (-)Ensembl
RefSeq Acc Id: NM_017044   ⟹   NP_058740
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81176,943,102 - 176,946,034 (-)NCBI
mRatBN7.21167,508,598 - 167,511,530 (-)NCBI
Rnor_6.01178,215,829 - 178,218,761 (-)NCBI
Rnor_5.01185,183,456 - 185,186,388 (-)NCBI
RGSC_v3.41171,240,596 - 171,243,528 (-)RGD
Celera1165,378,267 - 165,381,199 (-)RGD
Sequence:
RefSeq Acc Id: XM_039100789   ⟹   XP_038956717
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81176,942,901 - 176,944,311 (-)NCBI
mRatBN7.21167,508,121 - 167,509,807 (-)NCBI
RefSeq Acc Id: NP_058740   ⟸   NM_017044
- Peptide Label: precursor
- UniProtKB: Q63473 (UniProtKB/Swiss-Prot),   P04089 (UniProtKB/Swiss-Prot),   A6I885 (UniProtKB/TrEMBL),   Q80WZ2 (UniProtKB/TrEMBL)
- Sequence:
Ensembl Acc Id: ENSRNOP00000019199   ⟸   ENSRNOT00000019199
RefSeq Acc Id: XP_038956717   ⟸   XM_039100789
- Peptide Label: isoform X1
- UniProtKB: P04089 (UniProtKB/Swiss-Prot),   Q63473 (UniProtKB/Swiss-Prot),   A6I885 (UniProtKB/TrEMBL),   Q80WZ2 (UniProtKB/TrEMBL)

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P04089-F1-model_v2 AlphaFold P04089 1-115 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:6850034
Promoter ID:EP07108
Type:single initiation site
Name:RN_PTH
Description:Parathyroid hormone.
SO ACC ID:SO:0000170
Source:EPD (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Notes:homology_group=Homology group 171; Mammalian parathyroid hormone, promoter 1.
Tissues & Cell Lines:parathyroid gland
Experiment Methods:Nuclease protection with homologous sequence ladder; Sequencing of a full-length cDNA
Position:
Rat AssemblyChrPosition (strand)Source
RGSC_v3.41171,243,530 - 171,243,590EPD

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:3440 AgrOrtholog
BioCyc Gene G2FUF-57765 BioCyc
Ensembl Genes ENSRNOG00000014318 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000019199 ENTREZGENE
  ENSRNOT00000019199.3 UniProtKB/Swiss-Prot
InterPro PTH UniProtKB/Swiss-Prot
  PTH/PTH-rel UniProtKB/Swiss-Prot
KEGG Report rno:24694 UniProtKB/Swiss-Prot
NCBI Gene 24694 ENTREZGENE
PANTHER PARATHYROID HORMONE UniProtKB/Swiss-Prot
  PTHR10541 UniProtKB/Swiss-Prot
Pfam Parathyroid UniProtKB/Swiss-Prot
PhenoGen Pth PhenoGen
PIRSF PTH UniProtKB/Swiss-Prot
PROSITE PARATHYROID UniProtKB/Swiss-Prot
RatGTEx ENSRNOG00000014318 RatGTEx
SMART PTH UniProtKB/Swiss-Prot
UniProt A6I885 ENTREZGENE, UniProtKB/TrEMBL
  P04089 ENTREZGENE, UniProtKB/Swiss-Prot
  Q63473 ENTREZGENE
  Q80WZ2 ENTREZGENE, UniProtKB/TrEMBL
UniProt Secondary Q63473 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2002-06-10 Pth  parathyroid hormone      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_disease both inadequate and excessive secretion may lead to bone disorders 61525
gene_disease both inadequate and excessive secretion may lead to bone disorders 70297
gene_function induces intracellular calcium transients in osteoblastic cells, induces CREB phosphorylation through cAMP-dependent protein kinase A 61525
gene_function induces intracellular calcium transients in osteoblastic cells, induces CREB phosphorylation through cAMP-dependent protein kinase A 70297
gene_process stimulates anabolic and catabolic processes in bone 61525
gene_process stimulates anabolic and catabolic processes in bone 70297